Article

Elraglusib (9-ING-41), a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3, and enhances CD8+ T cell cytolytic killing of melanoma cells.

2022-05-11

Abstract excerpt

<h4>Background: </h4> Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with multiple roles in tumour growth, cell invasion and metastasis. We have previously established GSK-3 as an upstream regulator of PD-1 gene expression in CD8 + T cells and demonstrated that GSK-3 inhibition is as effective as anti-PD-1 mAb blockade in controlling tumour growth. Elraglusib (9-ING-41) is a specific small molecul...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7f03bed7-72d8-59ad-a307-65f67e2c0fdd
DOI: 10.21203/rs.3.rs-1629579/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Elraglusib (9-ING-41), a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3, and enhances CD8+ T cell cytolytic killing of melanoma cells.DOI 10.21203/rs.3.rs-1629579/v1Read

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeSemantic proximity Read

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling the responses of T-cells, myeloid derived suppressor cells and NK cellsSemantic proximity Read

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.Semantic proximity Read

G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in MelanomaSemantic proximity Read

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaSemantic proximity Read

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination With NivolumabSemantic proximity Read

Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy.Semantic proximity Read

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanomaSemantic proximity Read

Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent TumorigenesisSemantic proximity Read

GSK3beta: role in therapeutic landscape and development of modulators.Semantic proximity Read

The enzyme glycogen synthase kinase-3 is associated with specific forms of oncogenesis; what more do we need to know to achieve clinical benefit?Semantic proximity Read